Since 2002 Phenos has successfully completed more than 100 projects for customers in the pharmaceutical and biotech industry.
For confidentiality reasons we are not able to publish a complete customer list, but below you will find reference statements:

“In Phenos we found a flexible and knowledgeable Partner for our preclinical research. Based on a state of the art scientific background, Phenos’ people deliver results fast and reliable, contributing significantly to the acceleration of our own product development efforts.”
Paul  W. Th. J.  Leufkens,  Pharm.  D.,  MBA,  Director Product Development, Exponential Biotherapies, Inc. ("EBI")

“It has been great working with such an excellent and flexible CRO. The Phenos team is highly knowledgeable and scientifically sound. They provide robust, reproducible and translatable approaches. Many compliments to the team.”
Judit Molnar MD PhD, Senior Director Translational Medicine, Mission Therapeutics Ltd

“Developing drug combinations against AKI is one of our mainstay at Balmes Transplantation. We selected Phenos among other CROs in Europe for their extensive experience of the acute kidney injury models, both mastering the in vivo phase to reach excellent reproducibility and having access to a large panel of assays enabling sound and deep characterization of the mechanism of action of our drug combinations. We fully recommend Phenos' team for their scientific capabilities as well as for their personalized approach to solve the issues of their client.”
P. BERNA, Ph.D., CEO and Founder, Balmes Transplantation

“Phenos carried out early pre-clinical research feasibility studies for Boehringer Ingelheim. We were very pleased with the diligent and flexible conduct of the study, as well as the constructive discussions around the details and the on-time delivery of results. We would not hesitate to work with Phenos again in the future.”
Boehringer Ingelheim

“In Phenos we found a reliable partner who responds very well to individual wishes and gives valuable suggestions. Their approach creates an optimal starting point to achieve meaningful results for our research.”
Dr. Harald Tammen, CMO, PXBioVisioN GmbH